- Email: [email protected]
Echinococcus granulosus antigen protein sequence; DNA probe and vector expression in host; application as a recombinant vaccine
Helicobacter pylori recombinant CB antigen DNA sequence: antibody application in peptic ulcer disease diagnosis Vanderbilt Univ.
World 9316 723; 2 September 1993 The following are claimed: (a) a pure antigenic composition (CB antigen) comprising an antigen that specifically induces vacuolation of eukaryotic cells; (b) a gene comprising a DNA sequence encoding Helicobacter pylori vacuolating toxin or a fragment of it; (c) an antibody that specifically binds to H. pylori toxin, made by a process that produces antiserum or monoclonal antibodies to denatured or non-denatured CB antigen or to an antigenic composition as in (a); (d) a diagnostic test kit for detecting H. pylori infection comprising CB antigen; (e) a method in inhibiting H. pylori vacuolating toxin activity by administering a vacuolar ATPase-inhibitor (e.g. bafilomycin) in a carrier; and (f) a method to produce a recombinant vacuolating toxin or fragments by expressing all or part of the specified DNA sequence. The CB antigen can be used for inducing protective immunity against H. pylori infection and for the detection and production of antibodies. The nucleic acids, (a) and (b) can be used to detect the presence of infection with H. pylori and thus identifying patients at risk for peptic 022-94 ulcer disease or gastric malignancy.
Echinococcus granulosus antigen protein sequence; DNA probe and vector expression in host; application as a recombinant vaccine N.Z. Pastoral Agr. Res. Inst.; Univ. Melbourne World 9316 722; 2 September 1993 The following are claimed: (a) a new purified antigenic protein of mol wt. 23 000-25000, of specified protein sequence and which is capable of generating a protective immunological response to Echinococcus granulosus (EG) infection in a susceptible host; (b) a peptide fragment or variant of a protein as in (a); (c) a DNA molecule encoding a protein, fragment or variant as in (a) or (b); (d) a recombinant expression vector which contains a DNA molecule as in (c); (e) a host cell transformed with a vector as in (d) and capable of expressing the encoded protein, fragment or variant; (f) a purified antibody or binding fragment specific for a protein, fragment or variant as in (a) or (b); and (g) an optionally labelled DNA molecule of specified DNA sequence for use as a DNA probe to identify nucleic acid encoding a protective antigen of an Echinococcus or Taenia parasite other than EG. The protein, fragments, variants and DNA can be used as a recombinant vaccine to protect against infection by Echinococcus or Taenia parasites, particularly against cystic hydatid disease caused by EG in humans or domestic animals. 023-94
Vaccine 1994 Volume 12 Number 3
287
World 9316 723; 2 September 1993 The following are claimed: (a) a pure antigenic composition (CB antigen) comprising an antigen that specifically induces vacuolation of eukaryotic cells; (b) a gene comprising a DNA sequence encoding Helicobacter pylori vacuolating toxin or a fragment of it; (c) an antibody that specifically binds to H. pylori toxin, made by a process that produces antiserum or monoclonal antibodies to denatured or non-denatured CB antigen or to an antigenic composition as in (a); (d) a diagnostic test kit for detecting H. pylori infection comprising CB antigen; (e) a method in inhibiting H. pylori vacuolating toxin activity by administering a vacuolar ATPase-inhibitor (e.g. bafilomycin) in a carrier; and (f) a method to produce a recombinant vacuolating toxin or fragments by expressing all or part of the specified DNA sequence. The CB antigen can be used for inducing protective immunity against H. pylori infection and for the detection and production of antibodies. The nucleic acids, (a) and (b) can be used to detect the presence of infection with H. pylori and thus identifying patients at risk for peptic 022-94 ulcer disease or gastric malignancy.
Echinococcus granulosus antigen protein sequence; DNA probe and vector expression in host; application as a recombinant vaccine N.Z. Pastoral Agr. Res. Inst.; Univ. Melbourne World 9316 722; 2 September 1993 The following are claimed: (a) a new purified antigenic protein of mol wt. 23 000-25000, of specified protein sequence and which is capable of generating a protective immunological response to Echinococcus granulosus (EG) infection in a susceptible host; (b) a peptide fragment or variant of a protein as in (a); (c) a DNA molecule encoding a protein, fragment or variant as in (a) or (b); (d) a recombinant expression vector which contains a DNA molecule as in (c); (e) a host cell transformed with a vector as in (d) and capable of expressing the encoded protein, fragment or variant; (f) a purified antibody or binding fragment specific for a protein, fragment or variant as in (a) or (b); and (g) an optionally labelled DNA molecule of specified DNA sequence for use as a DNA probe to identify nucleic acid encoding a protective antigen of an Echinococcus or Taenia parasite other than EG. The protein, fragments, variants and DNA can be used as a recombinant vaccine to protect against infection by Echinococcus or Taenia parasites, particularly against cystic hydatid disease caused by EG in humans or domestic animals. 023-94
Vaccine 1994 Volume 12 Number 3
287